Migraines, a common health issue that affects millions of people worldwide, are about to meet a formidable opponent. The National Institute for Health and Care Excellence (NICE) in the UK has recommended a new drug, Rimegepant, for preventing migraines. This groundbreaking treatment, also known as Vydura, is manufactured by Pfizer and is taken as a wafer that dissolves under the tongue.
Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.
Scientists discover robust evidence that chronic fatigue syndrome is a biological illness – Immune signatures in blood point to distinct disease stages, open door to better diagnosis and treatment – Researchers identified distinct immune changes in patients diagnosed with chronic fatigue syndrome, known medically as myalgic encephalomyelitis (ME/CFS) or systemic exertion intolerance disease.
170 reportedly sickened by mold in Chobani yogurt – Complaints double from people attributing sickness to Chobani yogurt – As of September 13, the FDA received a total of 170 complaints associated with Chobani. The various issues reported continue to be cramps, nausea, headache and diarrhea. The complaints were submitted by individuals in Arizona, Delaware, New York, Maryland, Ohio, Pennsylvania, California, Indiana and Florida.
FDA Warns of Rare Acetaminophen Risk — Acetaminophen linked to three serious skin diseases – Acetaminophen, a fever and pain reliever that is one of the most widely used medicines in the U.S., can cause rare but serious skin reactions, warns the Food and Drug Administration (FDA).